1. Home
  2. CNEY vs ERNA Comparison

CNEY vs ERNA Comparison

Compare CNEY & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CN Energy Group Inc.

CNEY

CN Energy Group Inc.

N/A

Current Price

$0.45

Market Cap

2.4M

Sector

Industrials

ML Signal

N/A

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

N/A

Current Price

$2.00

Market Cap

2.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNEY
ERNA
Founded
2009
2018
Country
China
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4M
2.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
CNEY
ERNA
Price
$0.45
$2.00
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 330.7K
27.5K
Earning Date
02-17-2027
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.29
EPS
★ N/A
N/A
Revenue
N/A
★ $582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.31
$1.84
52 Week High
$2.63
$47.25

Technical Indicators

Market Signals
Indicator
CNEY
ERNA
Relative Strength Index (RSI) 44.65 32.38
Support Level $0.44 $1.84
Resistance Level $0.62 $2.26
Average True Range (ATR) 0.05 0.17
MACD 0.01 0.06
Stochastic Oscillator 51.12 29.99

Price Performance

Historical Comparison
CNEY
ERNA

About CNEY CN Energy Group Inc.

CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: